help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wada, S.
Right arrow Articles by Findlay, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wada, S.
Right arrow Articles by Findlay, D. M.
Endocrinology Vol. 138, No. 2 521-529
Copyright © 1997 by The Endocrine Society


Articles

Regulation by Calcitonin and Glucocorticoids of Calcitonin Receptor Gene Expression in Mouse Osteoclasts1

Seiki Wada, Nobuyuki Udagawa2, Takuhiko Akatsu, Naokazu Nagata, T. John Martin and David M. Findlay3

St. Vincent’s Institute of Medical Research (S.W.. N.U., T.J.M., D.M.F.), Fitzroy, Victoria, Australia; and the Third Department of Internal Medicine, National Defense Medical College (S.W., T.A., N.N.), Namiki, Tokorozawa, Saitama, Japan

Address all correspondence and requests for reprints to: Seiki Wada, M.D., Ph.D., Third Department of Internal Medicine, National Defense Medical College, 3–2 Namiki, Tokorozawa, Saitama 359, Japan.

We previously studied regulation of the calcitonin (CT) receptor (CTR) by glucocorticoid (GC) and CT in cultures of mature mouse osteoclast-like cells (OCLs). The present studies were designed to examine the interaction of CT and GC in regulation of the CTR in osteoclasts and the molecular mechanisms involved. Treatment of OCLs with 10-7 M dexamethasone (Dex) increased the CTR number in a time-dependent manner, whereas treatment with 10-9 M salmon CT (sCT) reduced CTR number; neither treatment changed receptor affinity. Dex pretreatment somewhat antagonized the CT-induced reduction in [125I]sCT specific binding. Dex increased, and sCT pretreatment decreased, the sCT-responsive adenylate cyclase activity in parallel with the change in receptor binding. Dex treatment resulted in an increase in CTR messenger RNA (mRNA) levels, as assessed by reverse transcription-PCR, indicating that the increased CTR number was mediated by de novo CTR synthesis. This effect was specific to GCs and was not reproduced by mineralocorticoids or sex steroids. Treatment with sCT resulted in a rapid and profound reduction in CTR mRNA expression, and this reductions was somewhat delayed by Dex pretreatment. OCLs were treated with 5,6-dichloro-1ß-D-ribofuranosyl benzimidazole to enable estimation of the mRNA decay rates in the absence of ongoing transcription. The stability of CTR mRNA was similar to the control value in Dex-treated OCLs, suggesting that the effect of Dex may be due to changes in transcriptional activity. Interestingly, transcriptional inhibition by 5,6-dichloro-1ß-D-ribofuranosyl benzimidazole abolished the ability of CT to reduce CTR mRNA levels, suggesting that CT may act by increasing the rate of CTR mRNA decay, and that this effect requires ongoing transcription. The 3'-untranslated region of the mouse CTR mRNA contains four copies of the AUUUA motif, as well as other A/U-rich sequences, which have been shown to determine the stability of other mRNA transcripts. The stability results were consistent with the results of the nuclear transcript run-on assay, which indicated that treatment with Dex enhanced the rate of transcription, whereas CT had no effect. These results show that GC and CT influence CTR expression by distinct mechanisms and provide the basis for identification of the cellular factors involved.




This article has been cited by other articles:


Home page
EndocrinologyHome page
C. Swanson, M. Lorentzon, H. H. Conaway, and U. H. Lerner
Glucocorticoid Regulation of Osteoclast Differentiation and Expression of Receptor Activator of Nuclear Factor-{kappa}B (NF-{kappa}B) Ligand, Osteoprotegerin, and Receptor Activator of NF-{kappa}B in Mouse Calvarial Bones
Endocrinology, July 1, 2006; 147(7): 3613 - 3622.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. Yasuda, S. Wada, Y. Arao, M. Kogawa, F. Kayama, and S. Katayama
Interaction between 3' Untranslated Region of Calcitonin Receptor Messenger Ribonucleic Acid (RNA) and Adenylate/Uridylate (AU)-Rich Element Binding Proteins (AU-Rich RNA-Binding Factor 1 and Hu Antigen R)
Endocrinology, April 1, 2004; 145(4): 1730 - 1738.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
H. Tsujikawa, Y. Kurotaki, T. Fujimori, K. Fukuda, and Y.-I. Nabeshima
Klotho, a Gene Related to a Syndrome Resembling Human Premature Aging, Functions in a Negative Regulatory Circuit of Vitamin D Endocrine System
Mol. Endocrinol., December 1, 2003; 17(12): 2393 - 2403.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Md. M. Rahman, A. Kukita, T. Kukita, T. Shobuike, T. Nakamura, and O. Kohashi
Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages
Blood, May 1, 2003; 101(9): 3451 - 3459.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. Wada, S. Yasuda, T. Nagai, T. Maeda, S. Kitahama, S. Suda, D. M. Findlay, M. Iitaka, and S. Katayama
Regulation of Calcitonin Receptor by Glucocorticoid in Human Osteoclast-Like Cells Prepared in Vitro Using Receptor Activator of Nuclear Factor-{{kappa}}B Ligand and Macrophage Colony-Stimulating Factor
Endocrinology, April 1, 2001; 142(4): 1471 - 1478.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
A. Samura, S. Wada, S. Suda, M. Iitaka, and S. Katayama
Calcitonin Receptor Regulation and Responsiveness to Calcitonin in Human Osteoclast-Like Cells Prepared in Vitro using Receptor Activator of Nuclear Factor-{kappa}B Ligand and Macrophage Colony-Stimulating Factor
Endocrinology, October 1, 2000; 141(10): 3774 - 3782.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
L. I. McKay and J. A. Cidlowski
Molecular Control of Immune/Inflammatory Responses: Interactions Between Nuclear Factor-{kappa}B and Steroid Receptor-Signaling Pathways
Endocr. Rev., August 1, 1999; 20(4): 435 - 459.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
D. Inoue, C. Shih, D. L. Galson, S. R. Goldring, W. C. Horne, and R. Baron
Calcitonin-Dependent Down-Regulation of the Mouse C1a Calcitonin Receptor in Cells of the Osteoclast Lineage Involves a Transcriptional Mechanism
Endocrinology, March 1, 1999; 140(3): 1060 - 1068.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
J. Rubin, D. M. Biskobing, L. Jadhav, D. Fan, M. S. Nanes, S. Perkins, and X. Fan
Dexamethasone Promotes Expression of Membrane-Bound Macrophage Colony-Stimulating Factor in Murine Osteoblast-Like Cells
Endocrinology, March 1, 1998; 139(3): 1006 - 1012.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society